S185. IMPACT OF GENETIC LIABILITY TO SCHIZOPHRENIA ON IMPAIRED MIGRATION OF AUTOLOGOUS INDUCED NEURAL STEM CELLS
Lee J., Song S., Young Lee T., Chang M., Soo Kwon J.
Prospective Study, published in Schizophr Bull (2020) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- Schizophr Bull (2020)
- Reported sample size
- —
- Source database
- Europe PMC
- PMCID
- PMC7234411
Abstract (original English)
Abstract Background Since previous studies which presented the direct evidences of neurodevelopmental abnormality in schizophrenia using stem cell techniques, recent studies have demonstrated that induced neural stem cells (iNSCs) derived from patients with schizophrenia resembling their fetal brain tissue indeed shows aberrant migration and maintains the gene signature. However, the origin and nature of these abnormalities remain unresolved and no study examined unaffected individuals (UIs) with multiple relatives with schizophrenia. Methods Three patients diagnosed as schizophrenia (SZs), 3 UIs who has multiple relatives diagnosed as schizophrenia including at least one first-degree relative, and 3 healthy controls (HCs), all males, were recruited from Seoul National University Hospital (SNUH), Korea. iNSCs were generated from human adipose-derived stem cells (hADSCs) using small molecule-based lineage switch technique. The NSC marker expressions in iNSCs were analysed by real-time polymerase chain reaction (qPCR). The migration of iNSCs was analysed by CytoSelect 96-well cell migration assay. Results Demographic characteristics were not significantly different among the groups. Level of functioning was significantly lower in SZs. Either mRNA levels of NSC markers or NCAM protein levels were not significantly different among the groups. Doubling time among the groups were not
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.